Form 8-K - Current report:
SEC Accession No. 0001193125-25-005014
Filing Date
2025-01-13
Accepted
2025-01-13 08:08:13
Documents
31
Period of Report
2025-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d910559d8k.htm   iXBRL 8-K 26548
2 EX-99.1 d910559dex991.htm EX-99.1 33392
3 EX-99.2 d910559dex992.htm EX-99.2 24568
7 GRAPHIC g910559ex99_2s10g1.jpg GRAPHIC 126815
8 GRAPHIC g910559ex99_2s11g1.jpg GRAPHIC 112646
9 GRAPHIC g910559ex99_2s12g1.jpg GRAPHIC 140676
10 GRAPHIC g910559ex99_2s13g1.jpg GRAPHIC 109249
11 GRAPHIC g910559ex99_2s14g1.jpg GRAPHIC 142701
12 GRAPHIC g910559ex99_2s15g1.jpg GRAPHIC 112256
13 GRAPHIC g910559ex99_2s1g1.jpg GRAPHIC 85839
14 GRAPHIC g910559ex99_2s2g1.jpg GRAPHIC 218788
15 GRAPHIC g910559ex99_2s3g1.jpg GRAPHIC 136717
16 GRAPHIC g910559ex99_2s4g1.jpg GRAPHIC 142147
17 GRAPHIC g910559ex99_2s5g1.jpg GRAPHIC 140753
18 GRAPHIC g910559ex99_2s6g1.jpg GRAPHIC 104611
19 GRAPHIC g910559ex99_2s7g1.jpg GRAPHIC 50059
20 GRAPHIC g910559ex99_2s8g1.jpg GRAPHIC 94370
21 GRAPHIC g910559ex99_2s9g1.jpg GRAPHIC 56982
22 GRAPHIC g910559snap1.jpg GRAPHIC 9369
  Complete submission text file 0001193125-25-005014.txt   2690296

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA spry-20250113.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE spry-20250113_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spry-20250113_pre.xml EX-101.PRE 11705
33 EXTRACTED XBRL INSTANCE DOCUMENT d910559d8k_htm.xml XML 3773
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 25524916
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)